Результаты поиска

:: 45th Ежегодное совещание Европейского общества по трансплантации крови и костного мозга: Врачи - сессия плаката.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Rapid Fire Presentations

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Uelkuemen Sara 1,2 , Sébastien Couillard-Després 3 , Gernot Michael Lang 2 1 Loretto Hospital, Spine Surgery, Freiburg, Germany, 2 Faculty of Medicine, University of Freiburg, Orthopedics and Trauma Surgery, Freiburg, Germany, 3 Paracelsus University Salzburg, Institute of Neuroregeneration, Salzburg, Austria …

Bispecific antibodies as powerful immunotherapeutic agents for urological cancers: Recent innovations based on preclinical and clinical evidence.

Conventional immunotherapy has emerged as a key option for cancer treatment. However, its efficacy has been limited in urological cancers, especially prostate cancer, because of the immunosuppressive tumor microenvironment (TME), difficulty in drug delivery, aberrant immune response, and damage to normal cells. Bispecific antibodies (BsAbs) are engineered proteins with two different antigen-binding domains, designed using different technologies and in various formats. BsAb-based tumor immunotherapy has yielded optimistic results in preclinical and clinical investigations of many tumor types, i

Совпадение в полном тексте источника
… 87189401 + JNJ-78278343 | CD28 PMSA + CD3 KLK2 | | Janssen Research & development, LLC | Advanced prostate cancer | Recruiting | 1 | United states | 2023- 11-01 | 2027- 06-21 | NCT06095089 BAY2010112 (Pasotuxizumab) | CD3 PMSA | BiTE | Bayer | Castration-resistant prostate cancer | Completed | 1 | Austria …

Unraveling Molecular and Genetic Insights into Neurodegenerative Diseases: Advances in Understanding Alzheimer's, Parkinson's, and Huntington's Diseases and Amyotrophic Lateral Sclerosis.

Neurodegenerative diseases are, according to recent studies, one of the main causes of disability and death worldwide. Interest in molecular genetics has started to experience exponential growth thanks to numerous advancements in technology, shifts in the understanding of the disease as a phenomenon, and the change in the perspective regarding gene editing and the advantages of this action. The aim of this paper is to analyze the newest approaches in genetics and molecular sciences regarding four of the most important neurodegenerative disorders: Alzheimer's disease, Parkinson's disease, Hunti

The underexplored links between cancer and the internal body climate: Implications for cancer prevention and treatment.

In order to effectively manage and cure cancer we should move beyond the general view of cancer as a random process of genetic alterations leading to uncontrolled cell proliferation or simply a predictable evolutionary process involving selection for traits that increase cell fitness. In our view, cancer is a systemic disease that involves multiple interactions not only among cells within tumors or between tumors and surrounding tissues but also with the entire organism and its internal "milieu". We define the internal body climate as an emergent property resulting from spatial and temporal in

Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

BACKGROUND: The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 comparative risk assessment (CRA) is a comprehensive approach to risk factor quantification that offers a useful tool for synthesising evidence on risks and risk-outcome associations. With each annual GBD study, we update the GBD CRA to incorporate improved methods, new risks and risk-outcome pairs, and new data on risk exposure levels and risk-outcome associations. METHODS: We used the CRA framework developed for previous iterations of GBD to estimate levels and trends in exposure, attributable deaths, and

Устные доклады

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Резюме 18th Неевромускульная научно-исследовательская конференция Соединенного Королевства 15th и 16th апрель 2025.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Determining Risk Factors Associated with Cardiovascular Complications in Patients with Acute Leukemia: A Systematic Review.

BackgroundPatients with acute leukemia (AL) are at heightened risk of cardiovascular complications due to both disease-related and treatment-related factors. These complications include heart failure, arrhythmias, myocardial infarction, and thromboembolic events which may significantly impact morbidity and mortality.ObjectiveTo identify the risk factors contributing to cardiovascular complications in patients with acute leukemia.MethodsThis systematic review was conducted according to the PRISMA reporting guideline. Multiple databases including PubMed, Scopus, IEEE Xplore, the Cochrane Library

Совпадение в полном тексте источника
… Additional contributions came from Austria, India, Greece, Croatia, Japan, and Switzerland (each with two studies), and single studies were from Romania, the United Arab Emirates, Slovenia, Colombia, Egypt, Serbia, Denmark, and Kosovo. …

Management of patients with an electrical storm or clustered ventricular arrhythmias: a clinical consensus statement of the European Heart Rhythm Association of the ESC-endorsed by the Asia-Pacific Heart Rhythm Society, Heart Rhythm Society, and Latin-American Heart Rhythm Society.

Electrical storm (ES) is a state of electrical instability, manifesting as recurrent ventricular arrhythmias (VAs) over a short period of time (three or more episodes of sustained VA within 24 h, separated by at least 5 min, requiring termination by an intervention). The clinical presentation can vary, but ES is usually a cardiac emergency. Electrical storm mainly affects patients with structural or primary electrical heart disease, often with an implantable cardioverter-defibrillator (ICD). Management of ES requires a multi-faceted approach and the involvement of multi-disciplinary teams, but

Резюме: 31 Европейский конгресс патологии.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Устные бесплатные бумажные сессии.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Ход работы сессии 31st Европейский педиатрический конгресс по педиатрии: часть 1.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… ankara, Türkiye; 22 Necker-Enfants Malades hospital, Paris, France; 23 University of L’Aquila, L’Aquila, Italy; 24 University of Leeds, Leeds, United Kingdom; 25 Université de Bordeaux, Bordeaux, France; 26 Wilhelmina Children’s Hospital, Utrecht, Netherlands; 27 Patient representative , Dornbirn, Austria …

Достижения в области диагностических средств и терапевтических подходов к глиомамам: всеобъемлющий обзор.

Глиомы, широко распространенная категория первичных злокачественных опухолей мозга, создают огромные клинические проблемы из-за их инвазивного характера и ограниченных возможностей лечения. Нынешний терапевтический ландшафт для глиомов сдерживается ".one-Эта парадигма подходит для всех, что существенно ограничивает эффективность лечения. Несмотря на осуществление стратегий мультимодального лечения, показатели выживаемости по-прежнему вызывают разочарование. Традиционный подход к лечению, предусматривающий хирургическое пересечение, излучение и химиотерапию, сталкивается с серьезными ограничени

Совпадение в полном тексте источника
… . | Part of an ongoing study, basket trial including 13 countries: Austria, Belgium, Canada, France, Germany, Italy, Japan, Netherlands, Norway, Republic of Korea, Spain, Sweden, and USA. | 2014–2018 | [ 29 ] Selinexor monotherapy in recurrent glioblastomas | Phase II open-label study NCT01986348 | Arm …

Interpreting Randomized Controlled Trials.

This article describes rationales and limitations for making inferences based on data from randomized controlled trials (RCTs). We argue that obtaining a representative random sample from a patient population is impossible for a clinical trial because patients are accrued sequentially over time and thus comprise a convenience sample, subject only to protocol entry criteria. Consequently, the trial's sample is unlikely to represent a definable patient population. We use causal diagrams to illustrate the difference between random allocation of interventions within a clinical trial sample and tru

New landscapes and horizons in hepatocellular carcinoma therapy.

Hepatocellular carcinoma (HCC), is the sixth most frequent form of cancer and leads to the fourth highest number of deaths each year. HCC results from a combination of environmental factors and aging as there are driver mutations at oncogenes which occur during aging. Most of HCCs are diagnosed at advanced stage preventing curative therapies. Treatment in advanced stage is a challenging and pressing problem, and novel and well-tolerated therapies are urgently needed. We will discuss further advances beyond sorafenib that target additional signaling pathways and immune checkpoint proteins. The

Совпадение в полном тексте источника
… However, a recently published paper conducted in Austria with a more innovative technique, confirmed previous observations obtained with RFTA, demonstrating that stereotactic radiofrequency ablation (SRFA) in octogenarians is a safe, feasible and useful option in the therapy of HCC with no significant …

Е-постеры.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Systematic review of the tools and outcomes for the assessment of acute radiation dermatitis severity.

Acute radiation dermatitis (ARD) is a common adverse effect experienced by patients undergoing radiation therapy. Effective assessment tools to accurately measure and manage ARD's impact on patients' quality of life and treatment outcomes is needed. The aim of this study was to evaluate the diverse tools and outcome measures used in the assessment of ARD. A systematic review of MEDLINE®, Embase, and Cochrane was conducted for records 1946-March 2024. A total of 423 studies, including 227 randomized controlled trials (RCTs), were included in the analysis. The review identified 58 distinct tools

Совпадение в полном тексте источника
… , 355 , 392 ] Israel | 0.9 % | [ 19 , 141 , 148 , 229 ] Czech Republic | 0.7 % | [ 95 , 315 , 430 ] Finland | 0.7 % | [ 287 , [387] , [388] ] Norway | 0.5 % | [ 98 , 138 ] Egypt | 0.5 % | [ 75 , 205 ] Ireland | 0.5 % | [ 305 , 312 ] Philippines | 0.5 % | [ 31 , 313 ] Ukraine | 0.5 % | [ 373 , 406 ] Austria …

Е-постеры.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Evidence for the use of intravenous immunoglobulins--a review of the literature.

Intravenous immunoglobulins (IVIg) were first introduced in the middle of the twentieth century for the treatment of primary immunodeficiencies. In 1981, Paul Imbach noticed an improvement of immune-mediated thrombocytopenia, in patients receiving IVIg for immunodeficiencies. This opened a new era for the treatment of autoimmune conditions with IVIg. Since then, IVIg has become an important treatment option in a wide spectrum of diseases, including autoimmune and acute inflammatory conditions, most of them off-label (not included in the US Food and Drug Administration recommendation). A panel

Совпадение в полном тексте источника
… as treatment RR = 0.36 ( p < 0.006) [ 145 ] Meta-analysis of 3 RCTs IVIg and phototherapy or phototherapy alone 189 patients Overall less use of exchange transfusion in the IVIg group: RR = 0.28 ( p < 0.00001) Hemolytic transfusion reaction [ 146 ] Case series IVIg (Endobulin HT, Immuno AG, Vienna, Austria … RR = 0.36 ( p < 0.006) [ 145 ] | Meta-analysis of 3 RCTs | IVIg and phototherapy or phototherapy alone | 189 patients | Overall less use of exchange transfusion in the IVIg group: RR = 0.28 ( p < 0.00001) Hemolytic transfusion reaction | [ 146 ] | Case series | IVIg (Endobulin HT, Immuno AG, Vienna, Austria …